Vanguard Group Inc. Acquires 303,912 Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO)

Vanguard Group Inc. raised its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 5.2% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 6,153,812 shares of the biopharmaceutical company’s stock after buying an additional 303,912 shares during the period. Vanguard Group Inc. owned approximately 5.95% of Juno Therapeutics worth $136,553,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Norges Bank acquired a new position in shares of Juno Therapeutics during the fourth quarter worth about $13,993,000. First Trust Advisors LP boosted its position in shares of Juno Therapeutics by 47.1% in the first quarter. First Trust Advisors LP now owns 1,377,667 shares of the biopharmaceutical company’s stock worth $30,570,000 after buying an additional 440,984 shares in the last quarter. BB Biotech AG boosted its position in shares of Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock worth $48,485,000 after buying an additional 315,000 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Juno Therapeutics by 1.2% in the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock worth $248,481,000 after buying an additional 135,908 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Juno Therapeutics by 31.1% in the first quarter. Ameriprise Financial Inc. now owns 470,741 shares of the biopharmaceutical company’s stock worth $10,446,000 after buying an additional 111,746 shares in the last quarter. Institutional investors own 64.51% of the company’s stock.

Shares of Juno Therapeutics, Inc. (JUNO) opened at 29.69 on Monday. The firm’s market cap is $3.09 billion. Juno Therapeutics, Inc. has a 12 month low of $17.52 and a 12 month high of $35.04. The company’s 50 day moving average is $26.64 and its 200-day moving average is $23.59.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.01. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The firm had revenue of $19.30 million for the quarter, compared to the consensus estimate of $16 million. During the same period in the prior year, the company earned ($0.78) EPS. The company’s revenue for the quarter was up 96.9% compared to the same quarter last year. Equities research analysts predict that Juno Therapeutics, Inc. will post ($2.98) EPS for the current year.

WARNING: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/07/24/vanguard-group-inc-acquires-303912-shares-of-juno-therapeutics-inc-nasdaqjuno.html.

JUNO has been the subject of a number of recent research reports. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research note on Tuesday, May 23rd. Wedbush restated a “neutral” rating and issued a $24.00 price objective on shares of Juno Therapeutics in a research note on Friday, May 5th. Morgan Stanley dropped their price objective on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research note on Monday, May 8th. Citigroup Inc. dropped their price objective on shares of Juno Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, April 4th. Finally, FBR & Co restated a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $30.81.

In related news, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total transaction of $262,500.00. Following the sale, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at approximately $22,085,670. The disclosure for this sale can be found here. Insiders have sold 8,041,500 shares of company stock valued at $217,230,360 in the last ninety days. 15.26% of the stock is currently owned by company insiders.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply